74/100
The estimated costs of dementia in LMICs are lower than in high-income countries. 3 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source
Research
27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
Little is known on how risk factors of younger cohorts will play out in the future burden of multi-morbidity (two or more concurrent long-term conditions). 2 key findings →
Design: longitudinal study Participants: 303,589 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
There is an extensive body of qualitative literature on the experiences of community-dwelling individuals with dementia on receiving and adapting to a diagnosis of dementia. 1 key finding →
Design: systematic review Participants: 3,095 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Sensitivity analyses suggest that these estimates are robust to the change in response. 2 key findings →
Participants: 2,500 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Researchers re-ran the same detailed dementia survey in the same three parts of England twenty years apart. 4 key findings →
Design: cross-sectional Participants: 15,431 Evidence: high
Full summary, score breakdown and related studies → Original source
Our aim was to review systematically the effectiveness of ACP interventions in people with cognitive impairment and dementia. 2 key findings →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source
Caring for people with dementia in primary care demands the same systematic approach as the management of other long-term conditions. 1 key finding →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source
Delirium increases risk of future cognitive decline and dementia, independent of illness severity and baseline cognition, with more episodes associated with worse cognitive outcomes. 5 key findings →
Participants: 205 Evidence: moderate
Full summary, score breakdown and related studies → Original source
59/100
Dramatic global increases in future numbers of people with dementia have been predicted. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The prevalence of comorbid conditions in people with dementia is high. 3 key findings →
Participants: 54 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Existing evidence regarding diagnostic disclosure in dementia is both inconsistent and limited with the perspectives of people with dementia being largely neglected. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
The significant challenges of providing good end of life care for people with dementia requires that different forms of expertise should be recognised and used; including the skills and knowledge of care assistants. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
This study has identified the professional, organisational and legal factors that influence advance care planning implementation; professional training should target these specific areas. 2 key findings →
Participants: 95 Evidence: low
Full summary, score breakdown and related studies → Original source
Health and social care professionals can build on people's preferences for informal planning by exploring the assumptions underlying them, providing information about the possible illness trajectory and discussing the options of care available. 1 key finding →
Participants: 17 Evidence: low
Full summary, score breakdown and related studies → Original source
This unique study has confirmed the relevance of much of the content of existing end of life frameworks to dementia. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Based on these findings, various actions are recommended for development, usability, effectiveness and cost-effectiveness, deployment, and ethics of assistive and health technologies across Europe. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
38/100
Seven areas were identified as important to end-of-life care for people with dementia and/or family carers. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Our findings reveal several different views on what is important about end-of-life care for people with dementia; therefore, a 'one-size-fits-all' approach to care is unlikely to be most appropriate. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Prototypes for two devices (armband and electronic notepad) were developed. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Where “Free full text” comes from
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomised / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multi-centre collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
What this library is — and isn't
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →